PARP inhibitors

News

A woman undertakes a mammogram with a female HCP

Lynparza boosts long-term survival in early breast cancer

A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.

News

Merck signs €1.4bn cancer alliance with China’s Hengrui

Germany’s Merck KGaA has reached a deal with Chinese pharma company Jiangsu Hengrui that covers a pair of cancer drugs, including a ‘next-generation’ PARP inhibitor and an

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in 2014 to treat ovarian cancer.

Events

Partner Content

PARP & DDR Inhibitors Summit 2021

Optimize PARP inhibitors in the clinic

News

Tesaro and Roche to combine drugs in bladder cancer trials

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

News

Rubraca outshines rivals in ovarian cancer maintenance thera...

Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.

Lynparza boosts long-term survival in early breast cancer

Merck signs €1.4bn cancer alliance with China’s Hengrui

AZ aims at Pfizer, GSK with potential new PARP cancer drug

PARP & DDR Inhibitors Summit 2021

Tesaro and Roche to combine drugs in bladder cancer trials

Rubraca outshines rivals in ovarian cancer maintenance thera...

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

PARP inhibitors

Editor's Picks